ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag hiv vaccine developmental biology microbiology

Updated July 9
Track COVID-19 Vaccines Advancing Through Clinical Trials
The Scientist | Apr 7, 2020 | 10+ min read
Find the latest updates in this one-stop resource, including efficacy data and side effects of approved shots, as well as progress on new candidates entering human studies.
New Era in Vaccine Development
Nadia Halim | Apr 16, 2000 | 6 min read
When all fails, try a new attack. That's exactly what researchers do when they use genome sequence data to develop vaccine candidates against the most difficult pathogenic adversaries. Recent efforts are revealing previously unknown microbial genes that may encode proteins important in triggering immunity. "Whole-genome data provides insight into all the features of [organisms] including access to virtually every single antigen that may provoke an immune response," explains Michael Gottlieb, pa
No Mo’ Slow Flow
Jeffrey M. Perkel | Jan 1, 2012 | 7 min read
Tools and tricks for high-throughput flow cytometry
The AIDS Research Evaluators
Lynn Gambale | Jul 9, 1995 | 6 min read
Chairman: Arnold Levine, chairman, department of molecular biology, Princeton University Barry Bloom, Weinstock Professor and Howard Hughes Medical Institute (HHMI) investigator, department of microbiology and immunology, Albert Einstein College of Medicine, New York Rebecca Buckley, professor of pediatrics and immunology, Duke University Medical Center Charles Carpenter, chairman, Office of AIDS Research Advisory Committee; professor of medicine,Brown University School of Medicine Don
Bioterrorism Research: New Money, New Anxieties
John Dudley Miller | Apr 6, 2003 | 8 min read
Ned Shaw US scientists have reason to feel both heady and scared. The federal government recently released unprecedented billions of dollars to fund bioterrorism research. Yet, the merits of this sudden shift in focus are being debated, and some worry that the money will be squandered or wasted. "I have been really very upset by the focus on bioterrorism," says Stanley Falkow, professor of microbiology and immunology and of medicine at Stanford University. "Everybody's talking about it, but th
AIDS Research Progress Stymied By Narrow Focus, Critics Charge
Franklin Hoke | Jul 10, 1994 | 9 min read
Critics Charge Author: FRANKLIN HOKE, pp.1 Date: July 11,1994 Disputing what they see as unproductive preoccupation with HIV-specific studies, they step up campaign for a `wider window' of research Progress in AIDS research has faltered in the United States since the mid-1980s, according to some scientists, owing to a premature narrowing of the research focus by the scientific and administrative leadership of the National Inst
AIDS Research Progress Stymied By Narrow Focus, Critics Charge
Franklin Hoke | Jul 10, 1994 | 9 min read
Critics Charge Author: FRANKLIN HOKE, pp.1 Date: July 11,1994 Disputing what they see as unproductive preoccupation with HIV-specific studies, they step up campaign for a `wider window' of research Progress in AIDS research has faltered in the United States since the mid-1980s, according to some scientists, owing to a premature narrowing of the research focus by the scientific and administrative leadership of the National Inst
Scientific Misconduct: Red Flags
John R. Thomas Jr. | Dec 1, 2015 | 6 min read
Warning signs that scandal might be brewing in your lab
 
Observers Praise AIDS Report But Foresee Problems In Implementation
Steven Benowitz | May 12, 1996 | 10 min read
Problems In Implementation LOUD AND CLEAR: Attorney Lynda Dee stresses the need for communication among the institutes. When a federally appointed panel announced in March the results of its 15-month-long review of the United States government's AIDS research program, AIDS activists as well as scientists cheered. The National Institutes of Health's AIDS Research Program Evaluation Working Group's recommendations largely called for scrapping what the group saw as outdated and ineffective polic
AIDS Pandemic Provokes Alarming Reassessments Of Infectious Disease
Joshua Lederberg | Jul 11, 1993 | 5 min read
In 1900, infectious disease was the leading cause of mortality in the United States, accounting for at least 37 percent of deaths. By 1950, this had been mitigated to 6.8 percent and, by 1989, to 2.8 percent, with corresponding improvements in life expectancy. These numbers, of course, must be taken with a grain of salt, given the eventual preemptive role of infection in chronic illness, and many disorders whose infectious etiology is still to be recognized. Further, the relative importance

Run a Search

ADVERTISEMENT